Table 3. Logistic Regression Models Adjusting for Age, Sex, and Primary Care Provider Participation in the Primary Care Information Project

	All		PCMH Pilot Practices Removed
	OR^*	95% CI	OR^*	95% CI
Diabetes (only)
Diabetes-specific medications^†
Non-PCIP	1.14	0.81–1.60	1.12	0.79–1.58
PCIP	2.03^‡	1.08–3.83	1.76	0.96–3.24
Lipid-controlling medications^§
Non-PCIP	0.85	0.55–1.32	0.83	0.53–1.29
PCIP	1.64	0.73–3.65	1.59	0.73–3.44
Hypertension (only)
Hypertension-specific medications^‖
Non-PCIP	1.26^‡	1.15–1.38	1.26^‡	1.15–1.38
PCIP	1.24^‡	1.03–1.49	1.24^‡	1.03–1.48
Lipid-controlling medications^§
Non-PCIP	1.28^‡	1.13–1.44	1.28^‡	1.13–1.49
PCIP	1.11	0.86–1.44	1.16	0.90–1.50
Comorbid diabetes and hypertension
Diabetes-specific medications^†
Non-PCIP	1.03	0.90–1.18	1.05	0.92–1.21
PCIP	1.06	0.81–1.40	1.14	0.88–1.49
Hypertension-specific medications^‖
Non-PCIP	1.19^‡	1.04–1.36	1.19^‡	1.04–1.36
PCIP	1.10	0.84–1.44	1.10	0.85–1.43
Lipid-controlling medications^§
Non-PCIP	1.14	0.99–1.32	1.16	1.00–1.33
PCIP	1.26	0.93–1.72	1.25	0.94–1.68

↵* Odd ratios (OR) shown for changes in the odds of the proportion of members who are adherent (i.e., medication possession ratio ≥80%) from baseline to the end of the study.
↵† Diabetes therapeutic drug classes include biguanides, sulfonylureas, thiazolidinediones, insulins, dipeptidyl peptidase IV inhibitors.
↵‡ P values <.05.
↵§ Lipid-controlling therapeutic drug classes include HMG-CoA reductase inhibitors and fibric acid derivatives.
↵‖ Hypertension therapeutic drug classes include angiotensin-converting enzyme inhibitors, angiotensin II receptor antagonists, beta-adrenergic blocking agents, calcium channel blocking agents (dihydropyridines), phosphodiesterase inhibitors, thiazide diruetics.
CI, confidence interval; PCMH, patient-centered medical home; OR, odds ratio; PCIP, Primary Care Information Project.